Back
Open Access

Mavacamten eligibility in an Irish hypertrophic cardiomyopathy cohort

Session: ePosters in myocardial disease - hypertrophic cardiomyopathy (3)
Topic: Hypertrophic Cardiomyopathy
Speaker: Mr P. Kopp (Stony Brook, US)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Mr Paul Kopp

Stony Brook (United States of America)
0 follower

7 more presentations in this session

Usefulness of implantable loop recorders in patients with hypertrophic cardiomyopathy

Speaker: Doctor M. Figueiredo (Barreiro, PT)

Access
Abstract
Like
Thumbnail

Medical education significantly improves the recognition of red flags of transthyretin cardiac amyloidosis

Speaker: Doctor C. Rohani-Montez (London, GB)

Access
Abstract
Like
Thumbnail

Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment

Speaker: Doctor R. Sepp (Szeged, HU)

Access
Abstract
Like
Thumbnail

Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment

Speaker: Doctor H. Takacs (Szeged, HU)

Access
Abstract
Like
Thumbnail

Phenotypic expression and prognostic determinants in TPM1-associated hypertrophic cardiomyopathy: insights from a tertiary center cohort

Speaker: Doctor C. Gregorio (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Access the full session

ePosters in myocardial disease - hypertrophic cardiomyopathy (3)

Speakers: Mr P. Kopp, Doctor M. Figueiredo, Doctor C. Rohani-Montez, Doctor R. Sepp, Doctor H. Takacs...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources